BACKGROUND: Minimally invasive treatment may be an alternative to breast-conserving surgery. METHODS: A structured PubMed, Embase, Cochrane, and Web of Science search was performed. Endpoints studied were feasibility, completeness of ablation, timing of the sentinel node biopsy (SNB), imaging modalities, and treatment-related complications. RESULTS: A total of 24 articles were retrieved, and the level of evidence varied (2B-4). Mainly phase II studies with a treat-and-resect protocol were analyzed. Up to 100% completeness of ablation was reported for radiofrequency ablation (RFA), cryosurgery, and focused ultrasound (FUS). The oncologic results need further evaluation. Dynamic contrast enhanced MRI seems to be the best method for monitoring treatment response (77% sensitivity, 100% specificity). Ultrasound is suitable for guiding probes into the tumor. There is no consensus on the timing of the SNB. CONCLUSIONS: All studies on minimally invasive ablative modalities published so far show that these techniques are feasible and safe. At this stage only T1 tumors should be ablated in a clinical trial setting; it is unclear which of the modalities is most suitable.
BACKGROUND: Minimally invasive treatment may be an alternative to breast-conserving surgery. METHODS: A structured PubMed, Embase, Cochrane, and Web of Science search was performed. Endpoints studied were feasibility, completeness of ablation, timing of the sentinel node biopsy (SNB), imaging modalities, and treatment-related complications. RESULTS: A total of 24 articles were retrieved, and the level of evidence varied (2B-4). Mainly phase II studies with a treat-and-resect protocol were analyzed. Up to 100% completeness of ablation was reported for radiofrequency ablation (RFA), cryosurgery, and focused ultrasound (FUS). The oncologic results need further evaluation. Dynamic contrast enhanced MRI seems to be the best method for monitoring treatment response (77% sensitivity, 100% specificity). Ultrasound is suitable for guiding probes into the tumor. There is no consensus on the timing of the SNB. CONCLUSIONS: All studies on minimally invasive ablative modalities published so far show that these techniques are feasible and safe. At this stage only T1 tumors should be ablated in a clinical trial setting; it is unclear which of the modalities is most suitable.
Authors: Flemming Forsberg; Barry B Goldberg; Christopher R B Merritt; Laurence Parker; Andrea J Maitino; Juan J Palazzo; Daniel A Merton; Susan M Schultz; Laurence Needleman Journal: J Ultrasound Med Date: 2004-02 Impact factor: 2.153
Authors: F Izzo; R Thomas; P Delrio; M Rinaldo; P Vallone; A DeChiara; G Botti; G D'Aiuto; P Cortino; S A Curley Journal: Cancer Date: 2001-10-15 Impact factor: 6.860
Authors: H Mumtaz; M A Hall-Craggs; A Wotherspoon; M Paley; G Buonaccorsi; Z Amin; I Wilkinson; M W Kissin; T I Davidson; I Taylor; S G Bown Journal: Radiology Date: 1996-09 Impact factor: 11.105
Authors: Marilyn A Roubidoux; Michael S Sabel; Janet E Bailey; Celina G Kleer; Katherine A Klein; Mark A Helvie Journal: Radiology Date: 2004-12 Impact factor: 11.105
Authors: Hernan I Vargas; William C Dooley; Robert A Gardner; Katherine D Gonzalez; Rose Venegas; Sylvia H Heywang-Kobrunner; Alan J Fenn Journal: Ann Surg Oncol Date: 2004-02 Impact factor: 5.344
Authors: Guglielmo Manenti; Angela L Scarano; Chiara A Pistolese; Tommaso Perretta; Elena Bonanno; Augusto Orlandi; Giovanni Simonetti Journal: Breast Care (Basel) Date: 2013-10 Impact factor: 2.860
Authors: Hayden W Head; Gerald D Dodd; Ande Bao; Anuradha Soundararajan; Xavier Garcia-Rojas; Thomas J Prihoda; Linda M McManus; Beth A Goins; Cristina A Santoyo; William T Phillips Journal: Radiology Date: 2010-05 Impact factor: 11.105
Authors: S van Esser; G Stapper; P J van Diest; M A A J van den Bosch; J H G M Klaessens; W P Th M Mali; I H M Borel Rinkes; R van Hillegersberg Journal: Ann Surg Oncol Date: 2009-06-09 Impact factor: 5.344
Authors: Geshel David Guerrero López; Mario Francisco Jesús Cepeda Rubio; José Irving Hernández Jácquez; Arturo Vera Hernandez; Lorenzo Leija Salas; Francisco Valdés Perezgasga; Francisco Flores García Journal: Comput Math Methods Med Date: 2017-12-10 Impact factor: 2.238